Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “outperform” rating reissued by stock analysts at Leerink Swann in a report released on Friday, September 8th. They currently have a $15.00 target price on the biotechnology company’s stock. Leerink Swann’s price target points to a potential upside of 71.04% from the stock’s previous close.
A number of other analysts also recently weighed in on ADAP. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, July 12th. ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $12.08.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded down 1.02% during trading on Friday, hitting $8.77. The stock had a trading volume of 268,239 shares. Adaptimmune Therapeutics PLC has a 12-month low of $3.76 and a 12-month high of $9.29. The company’s market cap is $820.16 million. The company has a 50 day moving average of $8.77 and a 200-day moving average of $6.74.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). The company had revenue of $3.52 million during the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, equities analysts predict that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current year.
WARNING: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/16/adaptimmune-therapeutics-plcs-adap-outperform-rating-reaffirmed-at-leerink-swann.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NEA Management Company LLC lifted its position in Adaptimmune Therapeutics PLC by 21.7% in the 1st quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock valued at $66,263,000 after acquiring an additional 2,145,000 shares in the last quarter. Matrix Capital Management Company LP bought a new position in Adaptimmune Therapeutics PLC in the 2nd quarter valued at about $39,027,000. Tekla Capital Management LLC increased its stake in Adaptimmune Therapeutics PLC by 158.9% in the 1st quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock valued at $8,080,000 after buying an additional 900,000 shares during the last quarter. Baillie Gifford & Co. increased its stake in Adaptimmune Therapeutics PLC by 43.7% in the 2nd quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock valued at $5,941,000 after buying an additional 402,324 shares during the last quarter. Finally, AXA purchased a new stake in Adaptimmune Therapeutics PLC in the 1st quarter valued at about $4,959,000. 68.01% of the stock is currently owned by institutional investors and hedge funds.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.